Contact
searchSearch
HMP Global
Login
Videos
Progress and Unmet Needs in Post-IO Treatment for Metastatic RCC
03/19/2025
Neil Shah, MD
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah...
03/19/2025
Journal of Clinical Pathways
Zibelman Headshot
Videos
Exploring the Potential of Nivolumab and Axitinib in Renal Cell Carcinoma
03/11/2025
Matthew Zibelman, MD
Matthew Zibelman, MD, shares results from his study on combination systemic therapy with tyrosine kinase inhibitor nivolumab and immune checkpoint inhibitor axitinib for patients with metastatic renal cell carcinoma.
Matthew Zibelman, MD, shares results from his study on combination systemic therapy with tyrosine kinase inhibitor nivolumab and immune checkpoint inhibitor axitinib for patients with metastatic renal cell carcinoma.
Matthew Zibelman, MD, shares...
03/11/2025
Journal of Clinical Pathways
Doshi Headshot
Videos
Assessing Real-World Outcomes of First-Line Ipilimumab and Nivolumab for Advanced Renal Cell Carcinoma
02/18/2025
Sahil Doshi, MD
In this interview, Sahil Doshi, MD, discusses the outcomes of a recent trial he authored on first-line ipilimumab and nivolumab for metastatic renal cell carcinoma, highlighting its implications for clinical practice and payer considerations.
In this interview, Sahil Doshi, MD, discusses the outcomes of a recent trial he authored on first-line ipilimumab and nivolumab for metastatic renal cell carcinoma, highlighting its implications for clinical practice and payer considerations.
In this interview, Sahil Doshi,...
02/18/2025
Journal of Clinical Pathways
Headshot
Videos
The Role of ctDNA Clearance in RCC: Retrospective Analysis and Clinical Implications
02/13/2025
Adanma Ayanambakkam, MD
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma...
02/13/2025
Journal of Clinical Pathways
Renee Saliby, MD
Videos
Using Intermediate Endpoints to Evaluate the Efficacy of ICIs for Treating Metastatic Renal Cell Carcinoma
03/22/2024

Featuring Renée Saliby, MD

Featuring Renée Saliby, MD
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her...
03/22/2024
Journal of Clinical Pathways
Amanda Nizam, MD
Videos
The Potential of Enfortumab Vedotin After Maintenance Avelumab For Treating Patients With Advanced Urothelial Carcinoma: The UNITE Study
03/04/2024

Featuring Amanda Nizam, MD

Featuring Amanda Nizam, MD
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the...
03/04/2024
Journal of Clinical Pathways
Muneeb Alam
Videos
Defining the Features of Urothelial Carcinoma at ASCO GU 2024
02/21/2024
Syed Muneeb Alam, MD
Syed Muneeb Alam, MD, from Memorial Sloan Kettering Cancer Center, shares some details about the abstract he presented at ASCO GU 2024 on the definition, diagnosis, and new technologies available for physicians treating patients with...
Syed Muneeb Alam, MD, from Memorial Sloan Kettering Cancer Center, shares some details about the abstract he presented at ASCO GU 2024 on the definition, diagnosis, and new technologies available for physicians treating patients with...
Syed Muneeb Alam, MD, from...
02/21/2024
Journal of Clinical Pathways
Alexandra Sokolova video thumbnail.
Videos
Highlights and Key Takeaways in Prostate Cancer From ASCO GU 2024
02/15/2024
Alexandra Sokolova, MD
Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.
Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.
Alexandra Sokolova, MD, shares...
02/15/2024
Journal of Clinical Pathways
News
Treatment Patterns and Overall Survival for Patients With Metastatic Urothelial Carcinoma Following FDA Approval of Avelumab Maintenance Therapy
02/15/2024
Grace Taylor, MS, MA
A study by Haojie Li, MD, PhD, and colleagues evaluated real-world treatment patterns and overall survival for patients with mUC during the period between the approval of maintA and P+EV for use in the US.
A study by Haojie Li, MD, PhD, and colleagues evaluated real-world treatment patterns and overall survival for patients with mUC during the period between the approval of maintA and P+EV for use in the US.
A study by Haojie Li, MD, PhD,...
02/15/2024
Journal of Clinical Pathways
Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways
Neal Shore, MD, FACS.
Videos
Outcomes of Men With High-Risk, Biochemically Recurrent Prostate Cancer Who Discontinued Enzalutamide Monotherapy in the EMBARK Study
01/18/2024
Neal Shore, MD, FACS
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Neal Shore, MD, FACS, discusses...
01/18/2024
Journal of Clinical Pathways
Dr Jeff Yorio.
Videos
Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI
05/25/2023
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology,...
05/25/2023
Journal of Clinical Pathways
Conference Coverage
Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma
03/31/2023
Grace Taylor, MS, MA
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers...
03/31/2023
Journal of Clinical Pathways
News
Study Analyzes Cabozantinib Plus Nivolumab and Ipilimumab for Patients With aRCC Who Have IMDC Intermediate or Poor Risk Scores
03/30/2023
Grace Taylor, MS, MA
At the 2023 ASCO GU Cancers Symposium, Thomas Powles, MD, and colleagues presented an analysis of the phase 3 clinical trial COSMIC-313, which compared the use of cabozantinib (C) plus nivolumab (N) and ipilimumab (I) versus a placebo with N...
At the 2023 ASCO GU Cancers Symposium, Thomas Powles, MD, and colleagues presented an analysis of the phase 3 clinical trial COSMIC-313, which compared the use of cabozantinib (C) plus nivolumab (N) and ipilimumab (I) versus a placebo with N...
At the 2023 ASCO GU Cancers...
03/30/2023
Journal of Clinical Pathways
Manish Kohli
Videos
Analyzing the Cost-Effectiveness of Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer
03/10/2023
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the...
03/10/2023
Journal of Clinical Pathways
Clinical Outcomes With Early vs Late Ra-223 for Patients With Metastatic CRPC
Videos
Clinical Outcomes With Early vs Late Ra-223 for Patients With Metastatic CRPC
04/23/2021
Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.
Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.
Richard Lee-Ying, MD, discusses...
04/23/2021
Journal of Clinical Pathways
Real-World Use of Cabozantinib Plus Direct Oral Anticoagulants in RCC
Videos
Real-World Use of Cabozantinib Plus Direct Oral Anticoagulants in RCC
04/21/2021
04/21/2021
Journal of Clinical Pathways
Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
Videos
Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
03/23/2021
03/23/2021
Journal of Clinical Pathways
Prescribing Patterns in Metastatic Castrate-Sensitive Prostate Cancer
Insights From ASCO 2021
Prescribing Patterns in Metastatic Castrate-Sensitive Prostate Cancer
03/23/2021
Nataliya Mar, MD, UC Irvine Medical Center, Orange, CA, discusses results from a study exploring prescribing among patients with metastatic castrate-sensitive prostate cancer (CSPC). These results were presented at the virtual 2021 ASCO...
Nataliya Mar, MD, UC Irvine Medical Center, Orange, CA, discusses results from a study exploring prescribing among patients with metastatic castrate-sensitive prostate cancer (CSPC). These results were presented at the virtual 2021 ASCO...
Nataliya Mar, MD, UC Irvine...
03/23/2021
Journal of Clinical Pathways
Patterns and Predictors of Oral Anticancer Agent Use for Metastatic RCC
Videos
Patterns and Predictors of Oral Anticancer Agent Use for Metastatic RCC
03/18/2021
03/18/2021
Journal of Clinical Pathways
Treatment Patterns After PD1/L1 Inhibitor Discontinuation in Advanced Urothelial Carcinoma
Videos
Treatment Patterns After PD1/L1 Inhibitor Discontinuation in Advanced Urothelial Carcinoma
03/18/2021
03/18/2021
Journal of Clinical Pathways
Real-World Treatment Sequences After First-Line Therapy in Metastatic RCC
Videos
Real-World Treatment Sequences After First-Line Therapy in Metastatic RCC
03/18/2021
03/18/2021
Journal of Clinical Pathways
Higher Hospital Competition Associated With Improved Quality of Prostate Cancer Care
Videos
Higher Hospital Competition Associated With Improved Quality of Prostate Cancer Care
03/18/2021
03/18/2021
Journal of Clinical Pathways
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
Videos
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
03/12/2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses...
03/12/2021
Journal of Clinical Pathways
Conference Coverage
Advanced Oral Therapy Adherence Among Patients With Prostate Cancer
03/03/2021
03/03/2021
Journal of Clinical Pathways
Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer
Videos
Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer
02/25/2021
02/25/2021
Journal of Clinical Pathways
Impact of Oral Anticancer Agent Adherence on Survival Outcomes in Metastatic RCC
Videos
Impact of Oral Anticancer Agent Adherence on Survival Outcomes in Metastatic RCC
02/25/2021
02/25/2021
Journal of Clinical Pathways
Hospital Efficiency Impact on Quality of Prostate Cancer Care
Videos
Hospital Efficiency Impact on Quality of Prostate Cancer Care
02/24/2021
02/24/2021
Journal of Clinical Pathways
Provider Preferences for Prostate Cancer: Medical Oncologists vs Urologists
Videos
Provider Preferences for Prostate Cancer: Medical Oncologists vs Urologists
02/21/2021
02/21/2021
Journal of Clinical Pathways
Conference Coverage
Apalutamide Plus ADT Improves OS in Metastatic Castration-Sensitive Prostate Cancer
02/21/2021
02/21/2021
Journal of Clinical Pathways
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
Videos
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
02/19/2021
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the...
02/19/2021
Journal of Clinical Pathways
Radical Prostatectomy for Low-Risk Prostate Cancer: Incidence and Cost
Videos
Radical Prostatectomy for Low-Risk Prostate Cancer: Incidence and Cost
02/19/2021
02/19/2021
Journal of Clinical Pathways
Adoption of Avelumab for First-Line Maintenance Therapy of Urothelial Cancer in US
Videos
Adoption of Avelumab for First-Line Maintenance Therapy of Urothelial Cancer in US
02/18/2021
02/18/2021
Journal of Clinical Pathways
PTEN Loss of Function Associated With Worse Survival in Metastatic CRPC
Videos
PTEN Loss of Function Associated With Worse Survival in Metastatic CRPC
02/18/2021
02/18/2021
Journal of Clinical Pathways
Conference Coverage
Apalutamide Plus Abiraterone Extends Radiographic PFS in Metastatic Castration-Resistant Prostate Cancer
02/18/2021
02/18/2021
Journal of Clinical Pathways
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
Videos
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
02/17/2021
02/17/2021
Journal of Clinical Pathways
Symptom Burden, Functional Status of Hospitalized Patients With Genitourinary Cancers vs Other Cancers
Videos
Symptom Burden, Functional Status of Hospitalized Patients With Genitourinary Cancers vs Other Cancers
02/17/2021
02/17/2021
Journal of Clinical Pathways
Conference Coverage
Adverse Events in Patients With Prostate Cancer Receiving Apalutamide or Enzalutamide
02/15/2021
02/15/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Cardiotoxicity of Abiraterone vs Enzalutamide for Prostate Cancer
02/15/2021
02/15/2021
Journal of Clinical Pathways
Apalutamide Plus ADT Improves Long-Term Survival in Metastatic Castration-Sensitive Prostate Cancer
Videos
Apalutamide Plus ADT Improves Long-Term Survival in Metastatic Castration-Sensitive Prostate Cancer
02/14/2021
02/14/2021
Journal of Clinical Pathways
Apalutamide Added to Abiraterone Acetate Plus Prednisone Improves Outcomes in Metastatic CRPC
Videos
Apalutamide Added to Abiraterone Acetate Plus Prednisone Improves Outcomes in Metastatic CRPC
02/12/2021
02/12/2021
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use